Annual CFO
-$76.76 M
-$35.18 M-84.60%
December 31, 2023
Summary
- As of February 22, 2025, SMMT annual cash flow from operations is -$76.76 million, with the most recent change of -$35.18 million (-84.60%) on December 31, 2023.
- During the last 3 years, SMMT annual CFO has fallen by -$28.65 million (-59.55%).
- SMMT annual CFO is now -605.81% below its all-time high of $15.18 million, reached on January 31, 2017.
Performance
SMMT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$30.30 M
+$2.71 M+8.20%
September 30, 2024
Summary
- As of February 22, 2025, SMMT quarterly cash flow from operations is -$30.30 million, with the most recent change of +$2.71 million (+8.20%) on September 30, 2024.
- Over the past year, SMMT quarterly CFO has stayed the same.
- SMMT quarterly CFO is now -188.05% below its all-time high of $34.41 million, reached on October 31, 2016.
Performance
SMMT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$112.89 M
-$15.40 M-15.80%
September 30, 2024
Summary
- As of February 22, 2025, SMMT TTM cash flow from operations is -$112.89 million, with the most recent change of -$15.40 million (-15.80%) on September 30, 2024.
- Over the past year, SMMT TTM CFO has stayed the same.
- SMMT TTM CFO is now -479.79% below its all-time high of $29.72 million, reached on July 31, 2017.
Performance
SMMT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
SMMT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -84.6% | 0.0% | 0.0% |
| 3 y3 years | -59.5% | -683.6% | -171.5% |
| 5 y5 years | -118.7% | -251.8% | -370.1% |
SMMT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.6% | at low | -683.6% | +8.2% | -216.1% | at low |
| 5 y | 5-year | -269.8% | at low | -683.6% | +8.2% | -374.3% | at low |
| alltime | all time | -605.8% | at low | -188.1% | +8.2% | -479.8% | at low |
Summit Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.30 M(-8.2%) | -$112.89 M(+15.8%) |
| Jun 2024 | - | -$33.00 M(+9.5%) | -$97.49 M(+4.0%) |
| Mar 2024 | - | -$30.13 M(+54.9%) | -$93.76 M(+22.2%) |
| Dec 2023 | -$76.76 M(+84.6%) | -$19.46 M(+30.6%) | -$76.76 M(+47.3%) |
| Sep 2023 | - | -$14.90 M(-49.1%) | -$52.11 M(+13.9%) |
| Jun 2023 | - | -$29.27 M(+122.9%) | -$45.77 M(+28.2%) |
| Mar 2023 | - | -$13.13 M(-353.0%) | -$35.71 M(-14.1%) |
| Dec 2022 | -$41.58 M(-42.7%) | $5.19 M(-160.7%) | -$41.58 M(-25.7%) |
| Sep 2022 | - | -$8.55 M(-55.5%) | -$55.95 M(-21.2%) |
| Jun 2022 | - | -$19.22 M(+1.1%) | -$70.96 M(+0.1%) |
| Mar 2022 | - | -$19.00 M(+107.0%) | -$70.92 M(-2.3%) |
| Dec 2021 | -$72.59 M(+50.9%) | -$9.18 M(-61.0%) | -$72.59 M(+1.7%) |
| Sep 2021 | - | -$23.57 M(+22.9%) | -$71.38 M(+10.7%) |
| Jun 2021 | - | -$19.17 M(-7.2%) | -$64.46 M(+1.0%) |
| Mar 2021 | - | -$20.67 M(+159.3%) | -$63.82 M(+32.7%) |
| Dec 2020 | -$48.11 M(+131.8%) | - | - |
| Dec 2020 | - | -$7.97 M(-52.1%) | -$48.11 M(+19.9%) |
| Sep 2020 | - | -$16.65 M(-10.2%) | -$40.14 M(+25.0%) |
| Jun 2020 | - | -$18.53 M(+273.7%) | -$32.10 M(+34.9%) |
| Mar 2020 | - | -$4.96 M(-42.4%) | -$23.80 M(-0.9%) |
| Dec 2019 | -$20.76 M(-40.9%) | - | - |
| Oct 2019 | - | -$8.61 M(-15.8%) | -$24.02 M(+19.5%) |
| Jul 2019 | - | -$10.23 M(-667.1%) | -$20.10 M(-15.3%) |
| Apr 2019 | - | $1.80 M(-125.9%) | -$23.72 M(-32.4%) |
| Jan 2019 | -$35.11 M(+70.6%) | - | - |
| Jan 2019 | - | -$6.98 M(+48.6%) | -$35.11 M(-5.0%) |
| Oct 2018 | - | -$4.70 M(-66.1%) | -$36.96 M(-19.7%) |
| Jul 2018 | - | -$13.86 M(+44.7%) | -$46.05 M(+131.7%) |
| Apr 2018 | - | -$9.58 M | -$19.88 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2018 | -$20.58 M(-235.6%) | - | - |
| Jan 2018 | - | -$8.83 M(-36.0%) | -$20.58 M(+11.4%) |
| Oct 2017 | - | -$13.79 M(-211.9%) | -$18.47 M(-162.1%) |
| Jul 2017 | - | $12.32 M(-219.8%) | $29.72 M(+109.3%) |
| Apr 2017 | - | -$10.28 M(+53.1%) | $14.20 M(-6.4%) |
| Jan 2017 | $15.18 M(-162.0%) | - | - |
| Jan 2017 | - | -$6.72 M(-119.5%) | $15.18 M(+3.5%) |
| Oct 2016 | - | $34.41 M(-1172.5%) | $14.67 M(-156.1%) |
| Jul 2016 | - | -$3.21 M(-65.5%) | -$26.13 M(-6.1%) |
| Apr 2016 | - | -$9.31 M(+28.8%) | -$27.82 M(+13.7%) |
| Jan 2016 | -$24.47 M(+47.5%) | - | - |
| Jan 2016 | - | -$7.23 M(+13.1%) | -$24.47 M(+12.7%) |
| Oct 2015 | - | -$6.39 M(+30.5%) | -$21.71 M(+17.4%) |
| Jul 2015 | - | -$4.90 M(-17.9%) | -$18.48 M(-8.2%) |
| Apr 2015 | - | -$5.96 M(+33.5%) | -$20.13 M(+21.4%) |
| Jan 2015 | -$16.59 M(+71.3%) | - | - |
| Jan 2015 | - | -$4.46 M(+41.1%) | -$16.59 M(+36.8%) |
| Oct 2014 | - | -$3.16 M(-51.6%) | -$12.12 M(+35.3%) |
| Jul 2014 | - | -$6.54 M(+170.8%) | -$8.96 M(+270.8%) |
| Apr 2014 | - | -$2.42 M | -$2.42 M |
| Jan 2014 | -$9.68 M(+92.3%) | - | - |
| Jan 2013 | -$5.03 M(+32.4%) | - | - |
| Jan 2012 | -$3.80 M(-12.3%) | - | - |
| Jan 2011 | -$4.34 M(+63.9%) | - | - |
| Jan 2010 | -$2.65 M(-82.0%) | - | - |
| Jan 2009 | -$14.72 M(-8.7%) | - | - |
| Jan 2008 | -$16.13 M(+170.6%) | - | - |
| Jan 2007 | -$5.96 M(+266.4%) | - | - |
| Jan 2006 | -$1.63 M(-2978.2%) | - | - |
| Jan 2005 | $56.50 K | - | - |
FAQ
- What is Summit Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Summit Therapeutics?
- What is Summit Therapeutics annual CFO year-on-year change?
- What is Summit Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Summit Therapeutics?
- What is Summit Therapeutics quarterly CFO year-on-year change?
- What is Summit Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Summit Therapeutics?
- What is Summit Therapeutics TTM CFO year-on-year change?
What is Summit Therapeutics annual cash flow from operations?
The current annual CFO of SMMT is -$76.76 M
What is the all time high annual CFO for Summit Therapeutics?
Summit Therapeutics all-time high annual cash flow from operations is $15.18 M
What is Summit Therapeutics annual CFO year-on-year change?
Over the past year, SMMT annual cash flow from operations has changed by -$35.18 M (-84.60%)
What is Summit Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SMMT is -$30.30 M
What is the all time high quarterly CFO for Summit Therapeutics?
Summit Therapeutics all-time high quarterly cash flow from operations is $34.41 M
What is Summit Therapeutics quarterly CFO year-on-year change?
Over the past year, SMMT quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Summit Therapeutics TTM cash flow from operations?
The current TTM CFO of SMMT is -$112.89 M
What is the all time high TTM CFO for Summit Therapeutics?
Summit Therapeutics all-time high TTM cash flow from operations is $29.72 M
What is Summit Therapeutics TTM CFO year-on-year change?
Over the past year, SMMT TTM cash flow from operations has changed by $0.00 (0.00%)